Navigation Links
Cephalon Announces Issuance of Patent for AMRIX
Date:6/17/2008

FRAZER, Pa., June 17 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Patent and Trademark Office has issued a pharmaceutical formulation patent for AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). U.S. Patent No. 7,387,793 was issued to Eurand Inc., the developer of AMRIX, and expires on February 26, 2025. Last year, Cephalon acquired an exclusive license from Eurand to market AMRIX in North America. The issued claims cover Eurand's proprietary Diffucaps(R) technology used to formulate AMRIX as an extended-release capsule containing the muscle relaxant cyclobenzaprine. The AMRIX formulation allows, for the first time, a full day of cyclobenzaprine in a single dose medication for the treatment of acute painful musculoskeletal conditions.

"The issuance of this patent supports our investment in AMRIX and its innovative technology, which offers the only once-daily treatment option for patients suffering from acute muscle spasms," said Frank Baldino, Jr., Ph.D., Chairman and Chief Executive Officer. "Physician and patient response to AMRIX has resulted in strong prescription growth in 2008 and we expect that this product will be a key growth driver in our business for many years."

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products i
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
2. Cephalon Notified of Generic Fentanyl Buccal Tablet Filing
3. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
6. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
7. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
8. Cephalon General Counsel John E. Osborn to Resign Position
9. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...wire/ -- Researchers are taking a closer look at t...as studies continue to demonstrate that inhibiting...ports Genetic Engineering & Biotechnology New... cell growth, differentiation, and survival. In ad...ich plays a key role in cancer, according to the D...
(Date:12/4/2008)...ch of potential vaccine for low-resource countries... The biotech company Lentigen Corp...on PATH announced today a partnership to accelerat...ill initially invest $3 million over 27 months and...a H5N1 virus-like particle (VLP) prototype pandemi...
(Date:12/4/2008)... AC Immune SA, a leader,in Alzheim...t the World,Economic Forum has elected AC Immune ...s as an innovation leader and for its breakthrough...ness and society. , Furthermore, AC Immune ...,milestones in the development of innovative thera...
(Date:12/4/2008)...ire-FirstCall/ -- Raymond J. De Hont, Chairman and...YSE: MPR ), announced today that the Company,s Bo...2008, declared a quarterly dividend of $0.06 per s...record at the close of business on February 26, 20... the same period last year. , , This is the...
Breaking Biology Technology:GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 3Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Met-Pro Corporation Declares Quarterly Dividend 2
...Automotive supplier Johnson Controls unveiled it...ican International Auto Show in Detroit. The addit...build on their existing technology, increasing eas...markets. , ,Moving into a growing market, Johnson ...for hybrid electric vehicles. The NiMH, or nickel-...
...iation taps marketing firm for members ,The Wisc... has signed an agreement with Waukesha-based Avi...to its members. Avicom will become an agency of re... workshops on branding and other marketing issues ...lso launched a Web site called Biocom advertisin...
...cked out the Google Groups site. Google is alway...hat the old Usenet groups are all there (Google a...chnology, searching the group archives is like rev...ring in the names of some of my old co-workers and...sing on these ancient list servs. Here are all the...
...Froedtert Hospital and the Medical College of Wisc... and office space to their cancer center, to be co...0 million project, beginning this spring, that wil.... Froedtert is adding another 67,000 square feet t... outpatient services. , ,Froedtert President and C...
Other Biology Technology:Technology industry doesnt have a monopoly on speed 2Technology industry doesnt have a monopoly on speed 3
(Date:12/4/2008)... Springer as of January 2009. The official journal...viously published by Wiley-Blackwell, is respected...applied research articles in a broad range of subj...ished in English six times a year, Fisheries Scie...g a wide array of topics in both marine and freshw...
(Date:12/3/2008)...ce this week. The most exciting new film features ...ntists using ground-breaking technology. , For ...s Centenary Institute have filmed an immune cell b...fection as it begins to spread throughout the body...mune Imaging program at the Centenary Institute, s...
(Date:12/3/2008)...not help improve a person,s golf game, stream sala...he local country club in the near future, followin...re more than 17,000 golf courses in the United Sta...not used for playing," said Ray Semlitsch, Curator...and Science. "These managed green spaces aren,t su...
(Date:12/3/2008)...ctive gene into mouse blood cells, scientists at S...ed sickle cell disease pathology. In their studies...ed essentially no difference from normal mice. Alt...e therapy to humans presents significant technical... become an important treatment for the disease. ,...
Breaking Biology News(10 mins):Scientists film inner workings of the immune system 2Golf course: Playing fields, wildlife sanctuaries or both 2Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3NIDCR strategies for future scientific success 20293 1NIDCR strategies for future scientific success 20293 2Family Health International Featured at Global Health Council Conference 20289 1Family Health International Featured at Global Health Council Conference 20289 2Family Health International Featured at Global Health Council Conference 20289 3Family Health International Featured at Global Health Council Conference 20289 4ThreeWire Expands Presence in the Pharmaceutical Arena 5640 1ThreeWire Expands Presence in the Pharmaceutical Arena 5640 2Impliant Restarts Pivotal Clinical Trial for Patented TOPS 28TM 29 Spine System 2193 1Impliant Restarts Pivotal Clinical Trial for Patented TOPS 28TM 29 Spine System 2193 2Impliant Restarts Pivotal Clinical Trial for Patented TOPS 28TM 29 Spine System 2193 3
...ultured in the laboratory during in vitro fertilis...ociated with certain developmental syndromes and o... as low birth weight. , Researchers told the 22nd ... Reproduction and Embryology today (Monday) that p...n mouse embryos had shown that certain culture med...
...un Cohen of the Weizmann Institute of ScienceImmun...ism of a vaccine for Type 1 diabetes. The new find...vaccine, which is currently in advanced stages of ...disorder in which the immune system mistakenly att...ells, reducing and ultimately eliminating the prod...
...econd language. The Bowling Green State University...f proteins, especially the ones whose "talking" ai...talk, to each other," the associate professor says...t of the things that need to happen for living org...e has received $300,000 in funding from the Nation...
...tanding of time perception in the animal kingdom, ...tor, the bumble bee, can estimate the duration of ...nd annual rhythms of behavior, the more sophistica...me intervals had previously been known only in hum...ported by Michael Boisvert and David Sherry of the...
Other Biology News:How IVF could be causing genetic errors in embryos 2How IVF could be causing genetic errors in embryos 3The molecular mechanism of a diabetes vaccine revealed 2BGSU biologist trying to crack microscopic code 2BGSU biologist trying to crack microscopic code 3
...gn , Customer Peptide Synthesis , Containing on...ve 90%, 20 mg will be returned to customer conjuga... , Maintenance 102 days/each , Pre-immune ble...5 /each , Test bleed (app. 5 ml) x1 /each , ...
Mouse Serum • Mouse serum is collected off the clot fasted non-Swiss Albino mice of mixed sex and 8-12 weeks of age. Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2ED
10% Normal Goat Serum from Invitrogen
Human ICAT Affinity Purified Polyclonal Ab
Biology Products: